Product How it works Pricing Blog FAQ About Contact
Castle Biosciences

Castle Biosciences (NASDAQ: CSTL) net income

Castle Biosciences reported a net loss of $24.2m for fiscal 2025; in fiscal 2024 it reported a net profit of $18.2m. Earnings per share were −$0.83.

Castle Biosciences's best year of the last 8 was fiscal 2024. It reported a loss in 6 of those 8 years.

Net income, in millions of US dollars-6.420185.32019-10.32020-31.32021-67.12022-57.5202318.22024-24.22025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$24.2m−232.4%−7.0%−$0.83
2024$18.2m—5.5%$0.66
2023−$57.5m—−26.1%−$2.14
2022−$67.1m—−49.0%−$2.58
2021−$31.3m—−33.3%−$1.24
2020−$10.3m−294.9%−16.4%−$0.54
2019$5.3m—10.2%$0.35
2018−$6.4m—−27.9%−$5.33

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Castle Biosciences net income compared with its sector

By net income for its latest fiscal year, Castle Biosciences ranks 216th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Castle Biosciences, −7.0%.

RankCompanyNet incomeNet margin
214thInogen−$22.7m−6.5%
215thMirum Pharmaceuticals−$23.4m−4.5%
216thCastle Biosciences−$24.2m−7.0%
217thClearPoint Neuro−$25.5m−69.1%
218thTravere Therapeutics−$25.5m−5.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Castle Biosciences

How much did Castle Biosciences earn in fiscal 2025?
Castle Biosciences reported a net loss of $24.2m for fiscal 2025. In fiscal 2024 it reported a net profit of $18.2m.
What are the earnings per share of Castle Biosciences?
They were −$0.83 in fiscal 2025, compared with $0.66 in fiscal 2024.
What was the most profitable year for Castle Biosciences?
Of its last 8 fiscal years, fiscal 2024, with $18.2m.
Where does Castle Biosciences rank in its sector by net income?
It ranks 216th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Castle Biosciences come from?
From the annual report (Form 10-K) that Castle Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Castle Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Castle Biosciences: the Castle Biosciences page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.